Skip to content

Telomir Pharmaceuticals, Inc. Common Stock

TELO

$1.24

+$0.03 (2.48%)

After Hours

Loading chart...

IndexN/A

Market Cap0.04B

Enterprise Value0.04B

Income$-0.00B

Sales$0.00B

EmployeesN/A

P/E-4.28

P/SN/A

P/B7.12

P/C-11.41

EV/EBITDA-3.39

EV/SalesN/A

EPS (ttm)-0.29

EarningsN/A

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Volume0.05M

Shs Outstand0.03B

Change2.48%

Dividend Est.N/A

Dividend Ex-DateN/A

Perf YTDN/A

Perf YearN/A

Perf 3YN/A

Perf 5YN/A

Perf 10YN/A

IPON/A

Jun 1508:00AMTelomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model(accessnewswire.com)

May 2008:00AMTelomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease(accessnewswire.com)

Apr 3008:00AMTelomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer(accessnewswire.com)

Apr 2502:19AMTelomir Pharmaceuticals (NASDAQ:TELO) Trading 1.4% Higher – Here’s What Happened(defenseworld.net)

Apr 2409:00AMTelomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)(accessnewswire.com)

Apr 601:42AMHead to Head Review: Jaguar Animal Health (NASDAQ:JAGX) and Telomir Pharmaceuticals (NASDAQ:TELO)(defenseworld.net)

Mar 3108:00AMTelomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer(accessnewswire.com)

Feb 1708:00AMTelomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models(accessnewswire.com)

Feb 508:00AMTelomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging(accessnewswire.com)

Jan 2703:26AMTelomir Pharmaceuticals (TELO) to Release Quarterly Earnings on Tuesday(defenseworld.net)

Jan 1802:24AMFinancial Survey: Telomir Pharmaceuticals (NASDAQ:TELO) versus electroCore (NASDAQ:ECOR)(defenseworld.net)

Jan 508:00AMTelomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models(accessnewswire.com)

Dec 3002:55AMTelomir Pharmaceuticals (NASDAQ:TELO) Shares Down 8.9% – Here’s What Happened(defenseworld.net)

Dec 1807:30AMTelomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development(accessnewswire.com)

Nov 2508:00AMTelomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells(accessnewswire.com)

Nov 2107:30AMTelomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells(accessnewswire.com)

Nov 1208:00AMTelomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line(accessnewswire.com)

Oct 2307:30AMTelomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer's “Kill-and-Clean” Defense Systems in an Aggressive Prostate Cancer Model, Outperforming Rapamycin and Chemo(accessnewswire.com)

Oct 2107:30AMTelomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value Growth(accessnewswire.com)

Oct 1408:00AMTelomir Pharmaceuticals Announces New Data Showing That Telomir-1 Kills Aggressive Pancreatic Cancer Cells, One of the Deadliest Forms of Cancer(accessnewswire.com)

Oct 902:35PMTelomir Pharmaceuticals Touts Promising Action From Its Lead Breast Cancer Drug(benzinga.com)07:30AMTelomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells(accessnewswire.com)

Oct 707:30AMTelomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasis and Treatment Resistance(accessnewswire.com)

Sep 1808:00AMTelomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Targets Additional Histone Demethylase Families, a Unique Profile in Cancer and Aging Not Seen in Other Therapies(accessnewswire.com)

Sep 908:00AMTelomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor Suppressor, Outperforming Rapamycin and Chemotherapy(accessnewswire.com)

Aug 2808:00AMTelomir Pharmaceuticals Reports In Vitro Data Supporting the Potential of Telomir-1 as a First-in-Class Epigenetic Therapy Influencing DNA Methylation Pathways in Cancer, Aging, and Age-Related Diseases(accessnewswire.com)

Aug 708:00AMTelomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic Dysfunction(accessnewswire.com)

Jul 2408:00AMTelomir Pharmaceuticals Reports Telomir-1's Unique Profile Restores Mitochondrial Health While Improving Oxidative Stress Without Promoting Cell Proliferation in Diseased Human Cell Lines Highlighting Potential Relevance to Neurodegenerative Pathways in Alzheimer's and Parkinson's(accessnewswire.com)

Jul 1808:00AMTelomir Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and Rapamycin(accessnewswire.com)

Jun 1809:15AMTelomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid Aging(accessnewswire.com)

Insider Trading

Insider

Type

Shares

Price

Value

Date

Del Giudice Matthew Paul

Award

50.0K

$1.34

$67K

Apr 16, 26

MacPherson Edward Clouston

Award

50.0K

$1.34

$67K

Apr 16, 26

Whalen Matthew Pratt

Award

50.0K

$1.34

$67K

Apr 16, 26

Telomir Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical firm, concentrating its efforts on creating and launching novel therapeutic interventions. Its primary focus involves the development of TELOMIR-1, an innovative small molecule compound. This oral medication is being engineered to serve as a therapeutic solution against various age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, and also to assist in recovery post-chemotherapy. It achieves this by disrupting and inhibiting inflammatory pathways that are triggered by interleukin-17. Established in 2021, the company was initially known as Metallo Therapies Inc., officially adopting the name Telomir Pharmaceuticals, Inc. on October 10, 2022. The company's headquarters are located in Baltimore, Maryland.

CEO: Erez AminovEmployees: 2telomirpharma.com

Metric	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A
Gross Margin	0.00%	0.00%	0.00%	0.00%
Operating Expenses	$12.24M	$3.94M	$854.15K	$138.13K
Operating Income	$-12.24M	$-3.94M	$-854.15K	$-138.13K
Operating Margin	0.00%	0.00%	0.00%	0.00%
Net Income	$-16.53M	$-13.07M	$-854.15K	$-138.13K
Net Margin	0.00%	0.00%	0.00%	0.00%
EPS (Basic)	$-0.56	$-0.44	$-0.03	$-0.00
EBITDA	N/A	N/A	N/A	N/A
Stock Option Compensation Expense	N/A	N/A	N/A	N/A
Price To Earnings Ratio	N/A	N/A	N/A	N/A
Price To Sales Ratio	N/A	N/A	N/A	N/A
Shares Outstanding	N/A	N/A	N/A	N/A
Market Capitalization	N/A	N/A	N/A	N/A

Discover more

You may be interested in

Oracle Corp

$141.90

Walt Disney Co

$98.15

Adobe Inc

$251.34

Tesla Inc

$322.08

Abacus Global Management Inc

$10.63

Netflix Inc

$73.33

Visa Inc

$365.67

IBM Corp

$226.31

Alphabet Inc

$373.51

NVIDIA Corp

$206.64

Bank of America Corp

$62.48

Meta Platforms Inc

$590.24